GlassScriptPhysician profile
Bret A Belter
NPI 1578268751
$720.00
in general payments reported to CMS, 2019-2025
24 companies · $333 in 2025
The $333 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $387 · 2025: $333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $607 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $606.88 |
| Education | $113.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $95.00 | 2024 | Imbruvica |
| Pharmacosmos Therapeutics INC. | $74.36 | 2024-2025 | Monoferric |
| Sobi, INC | $71.37 | 2024 | |
| Daiichi Sankyo INC. | $55.14 | 2024-2025 | Enhertu |
| Novartis Pharmaceuticals Corporation | $44.12 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $43.78 | 2024 | |
| Abbvie INC. | $42.25 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.11 | 2024 | Hyqvia |
| Syndax Pharmaceuticals, INC. | $22.81 | 2025 | |
| Merck Sharp & Dohme LLC | $19.35 | 2024 | Keytruda, Lynparza |
| Servier Pharmaceuticals LLC | $18.67 | 2025 | |
| Astellas Pharma US INC | $18.12 | 2025 | Vyloy |
| Beone Medicines USA, INC. | $17.48 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $17.07 | 2025 | Libtayo |
| Genmab U.S., INC. | $16.42 | 2024 | Epkinly |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $15.92 | 2024 | Ayvakit |
| Avyxa Pharma, LLC | $15.51 | 2025 | |
| Gilead Sciences, INC. | $15.37 | 2025 | Trodelvy |
| Rigel Pharmaceuticals, INC. | $15.22 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Genentech USA, INC. | $15.02 | 2024 | Tecentriq, Alecensa |
| Octapharma USA, INC. | $14.92 | 2025 | Octagam Immune Globulin (Human) |
| Array Biopharma INC | $14.35 | 2024 | Mektovi, Braftovi, Tukysa |
| Jazz Pharmaceuticals INC. | $14.14 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $13.50 | 2025 | Onivyde |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bret Belter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.